While these results suggested that BAX499 is a candidate to treat hemophilia patients, a phase I trial evaluating ARC19499 was terminated due to the decreased TFPI clearance from aptamer binding and raising TFPI levels increased bleeding events [83]. This evidence concerns the gene TFPI and hemophilia.